Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Portfolio Pulse from
A Phase 3 trial revealed that the novel combination of Pozelimab and Cemdisiran (Poze-Cemdi) provides better control of intravascular hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria compared to the standard treatment, Ravulizumab.
December 08, 2024 | 12:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's novel Poze-Cemdi combination treatment demonstrated superior control of intravascular hemolysis in PNH patients compared to Ravulizumab in a Phase 3 trial.
The Phase 3 trial results indicate that Regeneron's Poze-Cemdi combination is more effective than the current standard treatment, Ravulizumab, in controlling PNH. This could lead to increased adoption and sales, positively impacting Regeneron's stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90